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Background
Cases of non-cirrhotic portal hypertension have been
reported in HIV-negative patients as a result from expo-
sure to adenosine analogues (e.g. azathioprine), bacterial
infections, trace metals and chemicals, genetic coagula-
tion disorders and/or autoimmune diseases. More
recently, reports of similar cases in HIV-positive individu-
als have attracted much attention.
Methods
Description of clinical and histological findings of all con-
secutive cases of SPH of unknown etiology seen in HIV
patients in three outpatient clinics in Spain.
Summary of results
A total of 13 (31.7%) out of 41 patients with unknown
liver disease were diagnosed with SPH. All had elevated
ALT for longer than 12 months and were followed for at
least 4 years in three HIV outpatient clinics in Spain and
in Italy.
Summary of results
The majority (85%) were males and homosexuals (77%),
with a median age of 50 years. The median time since HIV
diagnosis was over 7.5 years. All but one were on antiret-
roviral therapy and had undetectable plasma HIV-RNA.
None had current CD4 counts >200/mmc, although four
of them had CD4 nadir <cells/mmc any time in the past.
Median time of exposure to antiretroviral drugs in the 12
individuals on HAART was 50.5 months for didanosine,
21 months for stavudine and 18 months for nevirapine.
During follow-up, eight patients (61%) experienced com-
plications of SPH, including six upper gastrointestinal
bleeding from oesophageal varices, and five portal throm-
bosis. A liver biopsy was performed in all subjects; none
showed advanced hepatic fibrosis. Main features were as
follows: nodular regenerative hyperplasia (31%), perisi-
nusoidal fibrosis (8%), drug-induced hepatitis (8%),
NASH (31%), and unspecific lesions (22%).
Conclusion
A small subset of HIV patients may develop SPH in the
absence of known predisposing conditions and advanced
hepatic fibrosis. These patients may eventually experience
potentially fatal GI bleeding. Exposure to didanosine
seems to be involved in most cases. A primary injury of
the portal vessels by this adenosine analog may play a cen-
tral pathogenic role in this condition.
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